Quantcast
Last updated on April 17, 2014 at 11:32 EDT

Latest Pharmacogenetics Stories

2010-09-15 06:50:00

WASHINGTON and LONDON, September 15, 2010 /PRNewswire/ -- Diaceutics Limited (http://www.diaceutics.com) and London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, today announce a strategic partnership to develop software decision tools that will provide biopharmaceutical companies with rapid and extensive access to the world's leading academic biomarker research groups. The new tools will enable commercial biomarker research teams...

2010-08-10 07:00:00

CINCINNATI, Aug. 10 /PRNewswire/ -- AssureRx Health, Inc. today announced that it has received accreditation from the College of American Pathologists (CAP) for the delivery of high-quality, reliable laboratory pharmacogenetic testing services that meet or exceed regulatory laboratory standards and ensure commitment to patient care. The goal of the CAP Laboratory Accreditation Program is to improve patient safety by advancing the quality of pathology and laboratory services through...

2010-07-22 07:25:00

LONDON, July 22, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that it has augmented the strength of its team with the appointment of two senior advisers, Professors Stephen DeCherney and Munir Pirmohamed. With their extensive clinical, healthcare, and drug development expertise, their guidance will be invaluable to London Genetics. Stephen DeCherney MD, MPH, is Professor of...

2010-06-24 09:20:00

LOUISVILLE, Ky., June 24/PRNewswire/ -- PGXL, a Louisville-based molecular diagnostics laboratory, announced a new contractual agreement with Generation Health, Inc. (GH). The agreement makes PGXL a preferred genetic testing lab for GH. The lab will provide molecular diagnostic tests for GH, which will help physicians make therapeutic decisions and facilitate what has come to be known as "personalized medicine." "The affiliation with Generation Health takes our company, and the reality...

2010-05-12 07:05:00

LONDON, May 12, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce that the importance of this approach is being highlighted with the publication of its inaugural conference [1] proceedings in the May 2010 issue of Drug Discovery Today. The conference, 'Harnessing Genetic Knowledge To Improve Clinical Development and Patient Care'[2], brought together pharma and biotech companies,...

2010-03-23 07:00:00

CINCINNATI, March 23 /PRNewswire/ -- AssureRx Health, Inc., a personalized medicine company specializing in pharmacogenetic products to help physicians select the right drug and right dose for psychiatric patients, announced that Donald R. Wright, Jr. has been promoted to Senior Vice President, Operations and Technology. His expanded responsibilities include managing the Company's web-based software product development, overseeing information technology and molecular genetics laboratory...

2010-03-08 07:00:00

CINCINNATI, March 8 /PRNewswire/ -- AssureRx Health, Inc., a personalized medicine company focused on pharmacogenetics to aid in the treatment of patients with psychiatric disorders, today announced that it has added a fifth gene, CYP1A2, to its laboratory-developed pharmacogenetic test. GeneSightRx® measures and analyzes more than forty clinically important genetic variants that affect patients' response to medications prescribed in psychiatric medicine. The CYP1A2 gene...

2010-02-24 06:57:00

LONDON, February 24, 2010 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease. Financial details were not disclosed. The purpose of projects funded by the POC fund is to illustrate...

2010-02-21 13:11:41

Many people who undergo treatment for hepatitis C develop hemolytic anemia, a disorder that destroys red blood cells. In some cases, it is so severe they have to reduce their medication or stop therapy altogether. But now, scientists in Duke University's Institute for Genome Sciences & Policy (IGSP) have discovered two genetic alterations linked to a benign enzyme condition that keep some patients anemia-free. They say the discovery, appearing online in the journal Nature, opens the door...

2010-02-10 08:24:00

LONDON, February 10 /PRNewswire/ -- London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, is pleased to announce the launch of its expanded web site. The site, which was designed by Opus Design Consultants, highlights how pharmacogenetics can help to target drugs to those patients most likely to benefit, and to increase safety and cost-effectiveness. Working in partnership with its seven founding academic institutions, all with...